NCT04109508 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets | Biotech Hunter

Enrollment

278

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

December 24, 2020

Study Completion Date

January 27, 2021

Conditions

Healthy VolunteersType 2 Diabetes

Interventions

DRUG

Oral semaglutide

Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin